GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. - Wikidata - awgldk - TriplyDB

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.

http://www.wikidata.org/entity/Q34693220

about

Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review Hepatobiliary Tumors: Update on Diagnosis and Management Recent advances in multidisciplinary management of hepatocellular carcinoma Management of hepatocellular carcinoma with portal vein thrombosis Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Virus-induced hepatocellular carcinoma with special emphasis on HBV.Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.Ultrasound Elastography Used for Preventive Non-Invasive Screening in Early Detection of Liver Fibrosis Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data.Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort Evolving role of Sorafenib in the management of hepatocellular carcinoma.Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.Hepatocellular carcinoma: From diagnosis to treatment.Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model.Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives.Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?Refining sorafenib therapy: lessons from clinical practice.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.New treatment modalities for hepatocellular cancer.Sorafenib: 10 years after the first pivotal trial.

P2860

Q26740315-CF88E9C8-0ED7-4876-8C6C-3721679FC3DC Q26765210-3628E44C-0391-4BCC-8567-CD8C34FA2AE5 Q26772299-783EC1FA-32E1-4711-91A1-A0AADFB4795C Q26775654-B8DBD8F3-7AF9-4AAC-B8F6-3A325BB38F0D Q26863748-1DED1D5D-7935-4484-9ABC-166DCDAC0587 Q26996578-38AE610B-0013-41D3-BC63-F719C6BC6C2B Q28079378-F5B9C8D1-3721-48E7-B80E-F33E9FC7877A Q28392783-74D74098-1B3A-47A7-ACDA-D7001D3A9D9B Q28394414-D3CD10E6-4A57-4212-A848-CACDBA529535 Q30238961-BA10E805-4E52-405F-94F1-CB2FA15B2E56 Q30275646-D112F452-89E8-44C0-9BAE-9F9E60D12638 Q30376269-7793D492-7A13-4C85-9D59-B24C3C1B7164 Q31036824-9F1D1FA1-D407-4468-8ED8-5767943E19B4 Q31048824-97CA67ED-DD8F-41DB-9D44-9643BDBC67D8 Q33572657-102C3E6F-771D-4E75-977D-23A2B04DD59C Q33779864-CBE61F07-3001-4CAB-8575-EDB88D71BD02 Q34552160-D0550BF9-A2F6-404B-9075-333B2DC7FA4D Q34728237-9FFEE39D-267F-429D-94F6-CD761C8DE393 Q35051975-A296A658-6E55-4DA6-95A0-1B817B926E95 Q35167764-25D57624-34D4-4752-AAB3-837AE358A20E Q35419331-6E462771-225D-44C0-8258-D3F98481CE71 Q35626761-A5909C0A-CD88-4DBC-9C28-7ABFF850748B Q35668716-40FA3A5E-4EC7-462E-A6B8-3AF5B1F06724 Q35838170-549AB9CD-BD90-41E6-9266-95FE723FC4AF Q35951070-2428A3D3-7F21-44D7-A322-BE8832E18FA8 Q36325065-9A528E63-8A09-407D-BC12-0BA9E11D009C Q36916295-FE5A2800-4157-4450-A748-907E3F7C6C74 Q37031712-522116A6-141C-4E08-995F-AD079F066353 Q37242363-BA3F7351-FEB4-4D80-AF54-65AAE637213B Q37252306-4F4A871B-4065-4913-B1FD-F64B5317F1A4 Q37433645-26B74942-36A0-4BF4-A360-00D8069DBDB7 Q37696388-1443D5FC-1719-40E2-9F6E-A4E56B053E40 Q37708002-EEBFFD82-FF55-492B-8655-FB48FD93C1AB Q37709404-5D9D19C9-819B-475A-9A43-778B41AC3FFF Q38213650-89FD2CD2-608C-4DAA-983E-0D296CABC37D Q38217457-9340E95B-2B21-4FA1-8A5B-3C57BD834BD7 Q38264146-3C1BE7C7-B228-4D4D-8976-0B891B8B5CE7 Q38388551-A35D2FB9-D375-4D71-9283-F7FE376127EF Q38419200-D9ED85A2-DF03-4EEE-A9E7-89A8D240940A Q38544841-EEC3F178-27F1-4AC0-B957-E6238EEFECD1

P2860

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.

http://www.wikidata.org/entity/Q34693220

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

GIDEON (Global Investigation o ...... Nib): second interim analysis.

@ast

GIDEON (Global Investigation o ...... Nib): second interim analysis.

@en

GIDEON

@nl

type

label

GIDEON (Global Investigation o ...... Nib): second interim analysis.

@ast

GIDEON (Global Investigation o ...... Nib): second interim analysis.

@en

GIDEON

@nl

prefLabel

GIDEON (Global Investigation o ...... Nib): second interim analysis.

@ast

GIDEON (Global Investigation o ...... Nib): second interim analysis.

@en

GIDEON

@nl

P1433

Q34693220-58AAF9D7-6BB6-4B30-A956-4B2CD2324BA9

P1476

Q34693220-CB5DB834-296B-47A7-A9D8-7E3DEE6EA0BE

P2093

Q34693220-05F73CCD-9C1D-42C9-91C6-62AA645100A1

Q34693220-14B3633B-6726-463D-8904-98F37265A401

Q34693220-2946224D-2ABE-4019-99B1-1EB5544505D9

Q34693220-442D0E57-FB3A-4836-8893-6B13357715D1

Q34693220-44F10188-6C72-4673-A2E7-FE90321D10D5

Q34693220-4AAB413C-3996-49C3-A4A5-1E926C8F6624

Q34693220-60E13738-F9CF-4EF9-B3C0-D40C5E060D0C

Q34693220-7C53F834-1155-4FD2-8C5C-D5F28AAA064F

Q34693220-8AF3BF40-5897-48EB-8262-E0B9990D4AE5

Q34693220-AE0A68EC-E0B0-4769-AA1F-FD0B3746D7FB

P2860

Q34693220-10E9D259-62CB-41EB-82D4-7FD2839BBFE2

Q34693220-11319336-5D5B-40C6-B218-2C590A9A0027

Q34693220-187771AF-6F3E-4E2C-ABD1-E4E87E5A455B

Q34693220-32E4E4E2-999F-4789-B331-2E672C16EFAD

Q34693220-425C5104-2A17-4B31-B250-3031FB62756A

Q34693220-4556DF1F-425B-4B05-9EF9-5078DFA4509A

Q34693220-51E78164-CE22-4746-8028-C5ED40697874

Q34693220-5BB12DA1-A743-47C1-BC98-371620CBFCF3

Q34693220-6094DF4D-0C89-4C1E-9D1F-45908777A474

Q34693220-79DF246A-82D6-454D-9A52-E9EF2CD6B263

P304

Q34693220-A91DB600-DC65-4FE4-9E10-B87BFAA650E8

P31

Q34693220-A825953E-2B18-4A55-B25D-6F5C98C2F3B9

P356

Q34693220-F3B628E4-26E8-45FC-AA67-BDC650974827

P433

Q34693220-AFEDD865-6BC0-4B31-93E5-6C4F3AD293C2

P478

Q34693220-9F98FB2B-2124-4CEF-B2D0-BF645FDBB53D

P50

Q34693220-575F8BCA-5068-44C3-A903-6BD9512FF58A

P577

Q34693220-EE7FFEB6-DADF-44C7-8C38-6D9993096C2D

P698

Q34693220-1784D7A2-E192-4079-8AA4-E322CAE0FB76

P932

Q34693220-B9A469AE-5943-4209-9310-46CCBC9A06F6

P356

P1433

International Journal of Clinical Practice

P1476

GIDEON (Global Investigation o ...... Nib): second interim analysis.

@en

P2093

A J Sanyal

http://www.w3.org/2001/XMLSchema#string

C Papandreou

http://www.w3.org/2001/XMLSchema#string

J F Geschwind

http://www.w3.org/2001/XMLSchema#string

J Furuse

http://www.w3.org/2001/XMLSchema#string

J-P Bronowicki

http://www.w3.org/2001/XMLSchema#string

K Nakajima

http://www.w3.org/2001/XMLSchema#string

L Dagher

http://www.w3.org/2001/XMLSchema#string

L Ladrón de Guevara

http://www.w3.org/2001/XMLSchema#string

R Lehr

http://www.w3.org/2001/XMLSchema#string

R Lencioni

http://www.w3.org/2001/XMLSchema#string

P2860

Risk factors of hepatocellular carcinoma--current status and perspectives

Management of hepatocellular carcinoma: An update

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma

Management of hepatocellular carcinoma

Epidemiology of viral hepatitis and hepatocellular carcinoma

Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.

Hepatocellular carcinoma: the need for progress.

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

P304

609-617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12352

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24283303

http://www.w3.org/2001/XMLSchema#string

P932

4265239

http://www.w3.org/2001/XMLSchema#string